Citius Pharma receives permanent J-code J9161 for LYMPHIR, effective April 1, 2025

Citius Pharmaceuticals, Inc.

CMS assigned permanent HCPCS J-code J9161 to LYMPHIR (denileukin diftitox-cxdl) for CTCL.
J-code effective April 1, 2025, streamlines billing and reimbursement for providers.
LYMPHIR approved by FDA for relapsed/refractory Stage I-III CTCL after prior systemic therapy.
CEO Leonard Mazur says J-code is critical for patient access and coverage by commercial & government insurers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.